[go: up one dir, main page]

Fan et al., 2013 - Google Patents

Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling

Fan et al., 2013

View HTML
Document ID
12668736103440274122
Author
Fan M
Sidhu R
Fujiwara H
Tortelli B
Zhang J
Davidson C
Walkley S
Bagel J
Vite C
Yanjanin N
Porter F
Schaffer J
Ory D
Publication year
Publication venue
Journal of lipid research

External Links

Snippet

Niemann-Pick type C (NPC) 1 is a rare neurodegenerative disease for which treatment options are limited. A major barrier to development of effective treatments has been the lack of validated biomarkers to monitor disease progression or serve as outcome measures in …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids

Similar Documents

Publication Publication Date Title
Fan et al. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling
Nicoli et al. GM1 gangliosidosis—A mini-review
Praggastis et al. A murine Niemann-Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele
Schuchman et al. Types A and B niemann-pick disease
Pelled et al. Enhanced calcium release in the acute neuronopathic form of Gaucher disease
Pchelina et al. Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases
JP7414750B2 (en) Markers of acid sphingomyelinase disorders and their use
Mattsson et al. Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in Niemann–Pick type C
Lee et al. AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse
TW201142297A (en) Urinary triaosylceramide (Gb3) as a marker of cardiac disease
Patterson et al. Niemann-Pick disease, type C and roscoe brady
Zhang et al. Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
Pandey et al. Metabolomics profiling reveals distinct, sex‐specific signatures in serum and brain metabolomes in mouse models of Alzheimer's disease
Lane et al. Glial activation mediates phenotypic effects of APOEε4 and sex in Alzheimer’s disease
Heinecke et al. Lipid composition of whole brain and cerebellum in Hurler syndrome (MPS IH) mice
Nadjar et al. Niemann-pick disease type C
Stern et al. Evaluation of the Landscape of Pharmacodynamic Biomarkers in GM1 and GM2 Gangliosidosis
Lane et al. Functional Glial Activation Mediates Phenotypic Effects of APOEɛ4 and Sex in Alzheimer’s Disease
Kell et al. Secondary accumulation of lyso-platelet activating factors in lysosomal storage diseases
Wurster et al. CSF d18: 1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants
Chen et al. NDUFB7 mutations cause brain neuronal defects, lactic acidosis, and mitochondrial dysfunction in humans and zebrafish
HK40021352A (en) Recombinant human acid sphingomyelinase for use in treating human asmd
Caçote Investigation of GpNMB as a Biomarker for Niemann-Pick and Gaucher Disease
HK1217534B (en) Marker for acid sphingomyelinase disorders and uses thereof
OA17663A (en) Marker for acid sphingomyelinase disorders and uses thereof.